Skip to main content

Table 1 Demographic and clinical characteristics (populations A and B)

From: New method for the mathematical derivation of the ventilatory anaerobic threshold: a retrospective study

 

Population A healthy (n = 67)

Population A with CV risks (n = 20)

Population A cardiac (n = 41)

Population B cardiac (n = 163)

Age, y

37 ± 20*

59 ± 11

67 ± 9

63 ± 10

Sex (male/female)

48/19

20/0

26/15

141/22

Body weight, kg

62 ± 11*

72 ± 7

59 ± 9

66.1 ± 10.9

Body mass index, kg/m2

22.1 ± 3.0*

25.8 ± 2.8

23.3 ± 3.1

24.7 ± 3.2

Heart disease etiology: ischemic (%)

NA

NA

76

84

Weber class: A/B/C/D

NA

NA

  

 Using VO2peak (n)

  

7/12/20/2

NA

 Using VAT (n)

  

1/16/18/6

11/40/66/29

Medications (n)

NA

   

 ACE or ARB

 

9

16

91

 Diuretic

 

2

7

51

 Beta-blocker

 

0

17

72

 Inotropics

 

0

0

4

 Ca channel blocker

 

17

7

35

 Anti-lipidemic

 

3

16

85

 Anti-diabetic

 

2

4

42

  1. *p-Value was significant at least at < 0.05 by 1-way analysis of variance
  2. Weber-Janicki functional classification: Using VO2peak, based on VO2peak; Using VAT, based on the ventilatory anaerobic threshold
  3. CV cardiovascular, ACE angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, Ca calcium